Page 114 - Athletic Health Handbook
P. 114
References

22. European Medicines Agency. European Medicines Agency update on non-selective NSAIDs. 2006.
http://www.emea.eu.int/pdfs/human/press/pr/298964005en.pdf. Accessed July 12, 2006.

23. European Medicines Agency. European Medicines Agency concludes action on COX-2 inhibitors. 2006.
http://www.emea.eu.int/pdfs/human/press/pr/20776605en.pdf. Accessed July 12, 2006.

24. Zhang J, Ding E, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. JAMA.
2006;296:1619-32.

25. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA. 2006;296:1633-44.
26. Kearney P, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflamma-

tory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006;332:1302-08.
27. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-30.
28. Lewis J, Kimmel S, Localio A, et al. Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin

nonsteroidal anti-inflammatory drugs. Gastroenterology. 2005;129:1965-74.
29. Allison M, Howatson A, Torrance C, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory

drugs. N Engl J Med. 1992;327:749-54.
30. El-Serag H, Graham D, Richardson P, et al. Prevention of complicated ulcer disease among chronic users of nonsteroidal

anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002;162:105-10.
31. McAleer S, Majid O, Venables E, et al. Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular

administration in healthy volunteers. J Clin Pharmacol. 2007;47:13-8.
32. Novembre E, Calogero C, Mori F, et al. Biphasic anaphylactic reaction to ketorolac tromethamine. Int J Immunopathol

Pharmacol. 2006;19:449-50.
33. Singer A, Mynster C, McMahon B. The effect of IM ketorolac tromethamine on bleeding time: A prospective, interventional,

controlled study. Am J Emerg Med. 2003;21:441-3.
34. Tokish J, Powell E, Schlegel T, et al. Ketorolac use in the National Football League. The Phys and Sports Medicine. 2002;30:1-7.
35. Graham D. COX-2 inhibitors, other NSAIDs, and cardiovascular risk. JAMA. 2006:1653-56.
36. Singh G. Arthritis, rheumatism and aging medical information system post-marketing surveillance program. J Rheumatol.

2001:1174-79.

© AMERICAN ORTHOPAEDIC SOCIETY FOR SPORTS MEDICINE, 2008, ALL RIGHTS RESERVED

COX-2 INHIBITORS AND NON-SELECTIVE NSAIDS 114
   109   110   111   112   113   114   115   116   117   118   119